Please amend the application as follows:

In the claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

1. (canceled)

2. (currently amended) A formulation comprising:
(i) an inhibitor of carboxypeptidase U or a pharmaceutically acceptable salt thereof; and
(ii) a thrombin inhibitor or an ester or prodrug ~~derivative~~ thereof, or a salt and/or solvate of any of these, in admixture with a pharmaceutically acceptable adjuvant, diluent, or carrier, wherein the inhibitor of carboxypeptidase U is a compound of formula I



(I)

or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt,
wherein:
R_1 is selected from the group consisting of:

~~C_4-C_6 alkyl, substituted with one or more basic groups;~~

cycloalkyl, substituted with one or more basic groups;

heterocyclyl, comprising at least one nitrogen atom, and substituted with one or more basic groups;

heterocyclyl, comprising at least one hetero atom selected from S or O, and substituted with one or more basic groups; and

aryl, substituted with one or more basic groups;

R_2 is selected from the group consisting of H, acyl, acylamino, alkyl, alkylcarbamoyl, alkylthio, alkoxy, aroyl, aroylamino, aryloxy, arylthio, amidino, amino, aryl, carbamoyl, carboxy, cyano, cycloalkyl, formyl, guanidino, halogen, heterocyclyl, hydroxy, nitro, thiol, a Z_2N-CO-O- group, a ZO-CO-NZ- group, and a Z_2N-CO-NZ- group;

R_3 is selected from the group consisting of $COOR_5$, $SO(OR_5)$, SO_3R_5, $P{=}O(OR_5)_2$, $B(OR_5)_2$, $P{-}OR_5(OR_5)$, tetrazole, and a carboxylic acid isostere;

R_4 is SH, S-CO-C_1-C_6 alkyl, or S-CO-aryl;

R_5 is H, C_1-C_6 alkyl, or aryl;

R_6 is H or C_1-C_6 alkyl;

X is selected from the group consisting of O, S, SO, SO_2, $C(Z)_2$, N(Z), NR_6SO_2, and SO_2NR_6;

Y is $C(Z)_2$; and

Z is independently selected from the group consisting of H, C_1-C_6 alkyl, aryl, cycloalkyl and heterocyclyl.

3. (withdrawn) A formulation comprising:

(i) an inhibitor of carboxypeptidase U or a pharmaceutically acceptable salt thereof; and

(ii) a thrombin inhibitor or a derivative thereof,

in admixture with a pharmaceutically acceptable adjuvant, diluent, or carrier, wherein the inhibitor of carboxypeptidase U

is a compound of formula II,



(II)

or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, wherein:

R_7 is selected from the group consisting of:

C_1-C_6 alkyl, substituted with one or more basic groups;

cycloalkyl, substituted with one or more basic groups;

heterocyclyl, comprising at least one nitrogen atom, and substituted with one or more basic groups;

heterocyclyl, comprising at least one hetero atom selected from S or O, and substituted with one or more basic groups; and

aryl, substituted with one or more basic groups;

R_8 is selected from the group consisting of H, acyl, acylamino, alkyl, alkylcarbamoyl, alkylthio, alkoxy, aroyl, aroylamino, aryloxy, arylthio, amidino, amino, aryl, carbamoyl, carboxy, cyano, cycloalkyl, formyl, guanidino, halogen, heterocyclyl, hydroxy, nitro, thiol, Z_2N-CO-O-, ZO-CO-NZ-, and Z_2N-CO-NZ-;

R_9 is selected from the group consisting of $COOR_{11}$, $SO(OR_{11})$, SO_3R_{11}, $P{=}O(OR_{11})_2$, $B(OR_{11})_2$, $P{=}OR_{11}(OR_{11})$, tetrazole, and a carboxylic acid isostere;

R_{10} represents a  -group, or a  -group, or a  -group,

R_{11} is H, C_1-C_6 alkyl, or aryl;

R_{12} is C_1-C_6 alkyl, aryl, cycloalkyl, heterocyclyl, or an optionally N-substituted

H_2N-C(Z)-CONH-C(Z)- or H_2N-C(Z)- group;

R_{13} is H or C_1-C_6 alkyl;

X is selected from the group consisting of O, S, SO, SO_2, $C(Z)_2$, N(Z), $NR_{13}SO_2$, SO_2NR_{13}, $NR_{13}CO$, and $CONR_{13}$;

Y is selected from the group consisting of O, N(Z), S, $C(Z)_2$, and a single bond; and

Z is independently selected from the group consisting of H, C_1-C_6 alkyl, aryl, cycloalkyl, and heterocyclyl,

with the proviso that when X is O, S, SO, SO_2, N(Z), NR_7SO_2, SO_2NR_7, or NR_7CO, then Y is $C(Z)_2$ or a single bond.

4. (currently amended) The formulation according to claim 2 ~~or 3~~, wherein the thrombin inhibitor is a low molecular weight thrombin inhibitor.

5. (previously presented) The formulation according to claim 4, wherein the low molecular weight thrombin inhibitor is a peptide-based, amino acid-based, and/or peptide analogue-based, thrombin inhibitor with one to four peptide linkages.

6. (previously presented) The formulation according to claim 5, wherein the low molecular weight thrombin inhibitor is HOOC-CH_2-(R)Cgl-Aze-Pab-H or a prodrug thereof.

7. (previously presented) The formulation according to claim 6, wherein the prodrug is EtOOC-CH_2-(R)Cgl-Aze-Pab-OH.

8. (currently amended) The formulation according to claim 2 ~~or 3~~, wherein the molar ratio between the inhibitor of carboxypeptidase U and the thrombin inhibitor lies in the range of from ~~about~~ 1000:1 to ~~about~~ 1:1000.

9. (currently amended) A kit of parts comprising:
(i) a vessel comprising an inhibitor of carboxypeptidase U, or a pharmaceutically acceptable salt thereof;
(ii) a vessel comprising a thrombin inhibitor, or an ester or prodrug ~~derivative~~ thereof, or a salt and/or solvate of any of these; and
(iii) instructions for the sequential, separate or simultaneous administration of the inhibitors (i) and (ii) to a patient in need thereof, wherein the inhibitor of carboxypeptidase U is a compound according to claim 2 ~~or 3~~.

10. (canceled)

11. (withdrawn) The kit of parts according to claim 9, wherein the thrombin inhibitor is a low molecular weight thrombin inhibitor.

12. (withdrawn) The kit of parts according to claim 11, wherein the low molecular weight thrombin inhibitor is a peptide-based, amino acid-based, and/or peptide analogue-based, thrombin inhibitor with one to four peptide linkages.

13. (withdrawn) The kit of parts according to claim 12, wherein the low molecular weight thrombin inhibitor is HOOC-CH_2-(R)Cgl-Aze-Pab-H or a prodrug thereof.

14. (withdrawn) The kit of parts according to claim 13, wherein the prodrug is EtOOC-CH_2-(R)Cgl-Aze-Pab-OH.

15. (currently amended) The kit of parts according to claim 9, wherein the molar ratio between the inhibitor of carboxypeptidase U and the thrombin inhibitor lies in the range of from ~~about~~ 1000:1 to ~~about~~ 1:1000.

16. (currently amended) A kit of parts comprising:
(i) a formulation comprising an inhibitor of carboxypeptidase U, or a pharmaceutically acceptable salt thereof, in admixture with a pharmaceutically acceptable adjuvant, diluent, or carrier; and
(ii) a formulation comprising a thrombin inhibitor, or an ester or prodrug ~~derivative~~ thereof, or a salt and/or solvate of any of these, in admixture with a pharmaceutically acceptable adjuvant, diluent, or carrier,
wherein inhibitors (i) and (ii) are each formulated for administration in conjunction with the other, and wherein the inhibitor of carboxypeptidase U is a compound according to claim 2 ~~or 3~~.

17. (withdrawn) The kit of parts according to claim 16, wherein inhibitors (i) and (ii) are formulated for sequential, separate or simultaneous administration.

18. (canceled)

19. (withdrawn) The kit of parts according to claim 16, wherein the thrombin inhibitor is a low molecular weight thrombin inhibitor.

20. (withdrawn) The kit of parts according to claim 19, wherein the low molecular weight thrombin inhibitor is a peptide-based, amino acid-based, and/or peptide analogue-based, thrombin inhibitor with one to four peptide linkages.

21. (withdrawn) The kit of parts according to claim 20, wherein the low molecular weight thrombin inhibitor is HOOC-CH_2-(R)Cgl-Aze-Pab-H or a prodrug thereof.

22. (withdrawn) The kit of parts according to claim 21, wherein the prodrug is EtOOC-CH_2-(R)Cgl-Aze-Pab-OH.

23. (currently amended) The kit of parts according to claim 16, wherein the molar ratio between the inhibitor of carboxypeptidase U and the thrombin inhibitor lies in the range of from ~~about~~ 1000:1 to ~~about~~ 1:1000.

24. (canceled)

25. (currently amended) A method for the treatment of ~~a patient suffering from, or susceptible to, a condition in which inhibition of thrombin and/or inhibition of carboxypeptidase U are required or desired~~ thrombosis and/or hypercoagulability, which method comprises administering to ~~the~~ a patient in need thereof a therapeutically effective total amount of:

(i) an inhibitor of carboxypeptidase U, or a pharmaceutically acceptable salt thereof, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier; and
(ii) a thrombin inhibitor, or an ester or prodrug ~~derivative~~ thereof, or a salt and/or solvate of any of these, in admixture with a pharmaceutically acceptable adjuvant, diluent, or carrier, wherein the inhibitor of carboxypeptidase U is a compound according to claim 2 ~~or 3~~.

26. (withdrawn) The method according to claim 25, wherein the administration of inhibitors (i) and (ii) is sequential, separate or simultaneous.

27. (canceled)

28. (withdrawn) The method according to claim 25, wherein the thrombin inhibitor is a low molecular weight thrombin inhibitor.

29. (withdrawn) The method according to claim 28, wherein the low molecular weight thrombin inhibitor is a peptide-based, amino acid-based, and/or peptide analogue-based, thrombin inhibitor with one to four peptide linkages.

30. (withdrawn) The method according to claim 29, wherein the low molecular weight thrombin inhibitor is HOOC-CH_2-(R)Cgl-Aze-Pab-H or a prodrug thereof.

31. (withdrawn) The method according to claim 30, wherein the prodrug is EtOOC-CH_2-(R)Cgl-Aze-Pab-OH.

32. (currently amended) The method according to claim 25, wherein the molar ratio between the inhibitor of carboxypeptidase U and the thrombin inhibitor lies in the range of from ~~about~~ 1000:1 to ~~about~~ 1:1000.

33. (currently amended) A method for treatment of ~~a patient suffering from, or susceptible to, a condition in which inhibition of thrombin and/or inhibition of carboxypeptidase U are required or desired~~ thrombosis and/or hypercoagulability, which method comprises administering to ~~the~~ a patient in need thereof a formulation according to claim 2 ~~or 3~~.

34-40. (canceled)

41. (currently amended) The formulation according to claim 2 ~~or 3~~, wherein the basic group is selected from the group consisting of amino, amidino, and guanidino.

42. (currently amended) The formulation according to claim 2 ~~or 3~~, wherein the molar ratio between the inhibitor of carboxypeptidase U and the thrombin inhibitor lies in the range of from ~~about~~ 50:1 to ~~about~~ 1:50.

43-46. (canceled)

47. (currently amended) The kit of parts according to claim 9, wherein the molar ratio between the inhibitor of carboxypeptidase U and the thrombin inhibitor lies in the range from ~~about~~ 50:1 to 1:50.

48-53. (canceled)

54. (currently amended) The kit of parts according to claim 16, wherein the molar ratio between the inhibitor of carboxypeptidase U and the thrombin inhibitor lies in the range of from ~~about~~ 50:1 to ~~about~~ 1:50.

55-60. (canceled)

61. (currently amended) The method according to claim 25, wherein the molar ratio between the inhibitor of carboxypeptidase U and the thrombin inhibitor lies in the range of from ~~about~~ 50:1 to ~~about~~ 1:50.

62. (canceled)

63. (canceled)

64. (new) A method for reducing the risk of thrombosis and/or hypercoagulability, which method comprises administering to a patient a therapeutically effective total amount of:
(i) an inhibitor of carboxypeptidase U, or a pharmaceutically acceptable salt thereof, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier; and
(ii) a thrombin inhibitor, or an ester or prodrug thereof, or a salt and/or solvate of any of these, in admixture with a pharmaceutically acceptable adjuvant, diluent, or carrier,
wherein the inhibitor of carboxypeptidase U is a compound according to claim 2.